• Sign In
  • Home
  • News
    • Politics
      • White House
      • Senate
      • House
      • Campaigns
  • Policy
  • 2026 Election
  • Opinion
    • Editorials
    • Op-Eds
  • In Focus
  • Restoring America
  • Magazine
  • Watch
  • Sponsored
    • Powering Progress
    • ASAE – Association Leadership
    • Examining Tax Reform
    • Fix TSCA
    • National Parks
    • Inside the Corn Belt
    • Examining Transportation
  • TWS Archive
Search
LogoWashington Examiner
Subscribe
Advertisement
LogoWashington Examiner
Sign in
Subscribe
  • News
    • Politics
      • White House
      • Senate
      • House
      • Campaigns
    • Business
    • World
    • Investigations
    • Justice
    • Supreme Court
    • Crime
    • Entertainment
    • Washington Secrets
  • Policy
    • Defense
    • National Security
    • Energy and Environment
    • Education
    • Immigration
    • Finance and Economy
    • Healthcare
    • Foreign Policy
    • Tech
    • Infrastructure
    • Space
  • 2026 Election
  • America at 250
  • IN FOCUS
  • Commentary
    • Columnists
    • Editorials
    • Think Tanks
    • Beltway Confidential
    • Op-Eds
  • Restoring America
    • Patriotism and Unity
    • Faith, Freedom, and Self-Reliance
    • Courage, Strength, and Optimism
    • Equality, Not Elitism
    • Community and Family
    • Fairness and Justice
    • Mission
  • Watch
  • Magazine
    • Magazine
    • Quarterly Briefing
    • Archives
    • Games
  • Sponsored
    • Powering Progress
    • ASAE – Association Leadership
    • National Parks
    • Examining Tax Reform
    • Fix TSCA
    • Inside the Corn Belt
    • Examining Transportation
  • Newsletters
More
    Advertisement
    Home › Authors › Posts by Linda Johnson

    Linda Johnson

    Linda Johnson

    Read the latest stories and analysis from Linda Johnson.

    Viagra ads target women for 1st time Business

    Viagra ads target women for 1st time

    Linda Johnson · September 30, 2014 3:37 pm
    FDA OKs Merck drug, 1st in new cancer drug class Business

    FDA OKs Merck drug, 1st in new cancer drug class

    Linda Johnson · September 4, 2014 9:41 pm
    Allergan reviews meeting requests in takeover bid Business

    Allergan reviews meeting requests in takeover bid

    Linda Johnson · August 23, 2014 6:29 pm
    Allergan sues Valeant, claims fraud in buy attempt Business

    Allergan sues Valeant, claims fraud in buy attempt

    Linda Johnson · August 1, 2014 9:32 pm
    Advertisement
    Biotech drugmaker Amgen laying off at least 2,400 Business

    Biotech drugmaker Amgen laying off at least 2,400

    Linda Johnson · July 29, 2014 11:17 pm
    Pfizer’s 2Q profit sinks 79 pct but tops forecasts Business

    Pfizer’s 2Q profit sinks 79 pct but tops forecasts

    Linda Johnson · July 29, 2014 5:37 pm
    Merck 2Q profit more than doubles Business

    Merck 2Q profit more than doubles

    Linda Johnson · July 29, 2014 3:44 pm
    J&J 2Q profit climbs 13 percent on new-drug sales Business

    J&J 2Q profit climbs 13 percent on new-drug sales

    Linda Johnson · July 15, 2014 4:27 pm
    Advertisement
    Merck to pay $3.85B for hepatitis C drug developer Business

    Merck to pay $3.85B for hepatitis C drug developer

    Linda Johnson · June 9, 2014 7:31 pm
    New allergy tablets offer alternative to shots Business

    New allergy tablets offer alternative to shots

    Linda Johnson · June 2, 2014 10:54 am
    Nonprescription Nexium heartburn medicine launches Business

    Nonprescription Nexium heartburn medicine launches

    Linda Johnson · May 27, 2014 6:28 pm
    Pfizer ups offer for AstraZeneca again, to $119B Business

    Pfizer ups offer for AstraZeneca again, to $119B

    Linda Johnson · May 19, 2014 4:06 am
    Advertisement
    • 1
    • 2
    • 3
    • …
    • 10
    • ›Next page
    Page 1 of 10
    Advertisement
    LogoWashington Examiner
    Do Not Sell or Share My Personal Information
    Facebook
    Twitter
    Youtube

    NEWS

    • Politics
      • White House
      • Senate
      • House
      • Campaigns
    • Business
    • World
    • Investigations
    • Justice
    • Supreme Court
    • Crime
    • Washington Secrets
    • Entertainment
    • Sports

    POLICY

    • Defense
    • National Security
    • Energy
    • Immigration
    • Finance and Economy
    • Healthcare
    • Foreign Policy
    • Tech
    • Infrastructure
    • Space

    COMMENTARY

    • Columnists
    • Editorials
    • Think Tanks
    • Beltway Confidential
    • Op-Eds

    RESTORING AMERICA

    • Patriotism and Unity
    • Faith, Freedom, and Self-Reliance
    • Courage, Strength, and Optimism
    • Equality, Not Elitism
    • Community and Family
    • Fairness and Justice
    • Mission
    • WATCH
    • IN FOCUS
    • NEWSLETTERS
    • MAGAZINE ARCHIVE
    • Policies and Standards
    • Terms Of Service
    • Subscription Terms of Use
    • Privacy Policy
    • Your Privacy Choices
    • Transparency In Coverage
    • Advertise
    • Subscribe
    • Contact
    • Careers
    • Staff
    • About Examiner
    • Facebook
    • Twitter
    • © Copyright 2026. Washington Examiner. All Rights Reserved.